Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer by Ying-tao Lin, Ying-tao Lin, Chang Wang, Xiao-yan He, Qi-min Yao, Jian Chen

Subjects: Get full text

Cost-effectiveness of utidelone and capecitabine versus monotherapy in anthracycline- and taxane-refractory metastatic breast cancer by Mulan Chen, Heng Zhang, Xiaoyan He, Yingtao Lin

Subjects: Get full text

Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US... by Wanxian Zeng, Wanxian Zeng, Xueqiong Cao, Xueqiong Cao, Jingwen Lin, Jingwen Lin, Bin Zheng, Bin Zheng, Na Li, Na Li, Maobai Liu, Maobai Liu, Hongfu Cai, Hongfu Cai

Subjects: Get full text

Cost-effectiveness of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with highvolume, metastatic, hormone-sensitive prostate cancer by Huina Wu, Lei Sun, Rui Feng, Huiyue Zhang, Ke Tang, Shuo Wang, Jing Nie

Subjects: Get full text

Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China by Zhou C, Wei J, Xu K, Lin Y, Zhang L, Li X

Subjects: Get full text

Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis by Yan Li, Xueyan Liang, Huijuan Li, Tong Yang, Sitong Guo, Xiaoyu Chen

Subjects: Get full text

First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis by Xueyan Liang, Mingyu Meng, Shiran Qin, Xiaoyu Chen, Yan Li

Subjects: Get full text

Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer by Xueyan Liang, Xiaoyu Chen, Huijuan Li, Yan Li

Subjects: Get full text

Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis by Zhiwei Zheng, Yuxuan Lin, Yuxuan Lin, Hongfu Cai

Subjects: Get full text

INES: Interactive tool for construction and extrapolation of partitioned survival models by Vicente Gimeno-Ballester, Daniel Perez-Troncoso, Antonio Olry-Labry, David Epstein

Subjects: “…Partitioned survival model…”
Get full text

Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract canc... by Zhiwei Zheng, Ling Fang, Hongfu Cai

Subjects: Get full text

Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in Ch... by Huiqin Liu, Ying Wang, Qi He

Subjects: Get full text

Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China by Yanhong Liu, Rong Shao

Subjects: Get full text

Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective by Yingcheng Wang, Yingcheng Wang, Mingjun Rui, Mingjun Rui, Xin Guan, Xin Guan, Yingdan Cao, Yingdan Cao, Pingyu Chen, Pingyu Chen

Subjects: Get full text

Comparison of partitioned survival modeling with state transition modeling approaches with or without consideration of brain metastasis: a case study of Osimertinib versus pemetrex... by Yoon-Bo Shim, Byeong-Chan Oh, Eui-Kyung Lee, Mi-Hai Park

Subjects: “…Partitioned survival model…”
Get full text

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer by Xueyan Liang, Xiaoyu Chen, Huijuan Li, Yan Li

Subjects: Get full text

Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis by Xueyan Liang, Xiaoyu Chen, Huijuan Li, Xiaoxia Liu, Yan Li

Subjects: Get full text

Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis by Xiaoyan Liu, Xiaoyan Liu, Yitian Lang, Yahui Liao, Yizhun Zhu

Subjects: Get full text

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis by Hongfu Cai, Ling Fang, Jingwen Lin, Zhiwei Zheng

Subjects: “…partitioned survival model…”
Get full text

Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China by Jinhong Gong, Jinhong Gong, Dan Su, Jingjing Shang, Shan Xu, Lidan Tang, Zhiqiang Sun, Guangjun Liu

Subjects: Get full text